BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

NCT ID: NCT04150614

Last Updated: 2025-11-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-05-14
• Study Completion Date: 2026-07-31

Brief Summary

Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.

Detailed Description

Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications. This study will be an open-label, prospective trial randomizing patients at a 1:1 ratio, to either one of two 5-hydroxytrytamine 3 (5-HT3) antagonists, transdermal granisetron or intravenous (i.v.) ondansetron, in combination with other standard, routinely administered anti-emetic drugs (dexamethasone). Rescue antiemetics will be administered at any time during the study period for vomiting or severe nausea at the request of the patients or as recommended by the attending physicians. For the granisetron treatment arm, patients will be educated and instructed to self-administer a single transdermal granisetron patch one-two days (approximately 24-48 hours) prior to start of the preparative regimen. An additional dose of transdermal granisetron will be administered 7 days after the initial granisetron dose. For the ondansetron treatment arm, patients will receive the standard dose and schedule of intravenous ondansetron that is routinely administered for each respective preparative regimen. Use of rescue medications will be assessed daily during chemotherapy, and for 7 days after the last chemotherapy drug administration (delayed phase). Nausea, vomiting, and treatment-related side effects will be documented and followed during this same time period. A quality of life questionnaire (MDASI-BMT) will be administered at Day + 7 (7 days after day of infusion). All other aspects of patient care (i.e., chemotherapy administration, supportive care, etc.) and laboratory monitoring will adhere to the routine standard of care operating procedures for stem cell transplant patients.

Conditions

Nausea With Vomiting Chemotherapy-Induced

Keywords

Hematopoietic Stem Cell Transplantation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Arm 1

ARM 1 -transdermal granisetron plus intravenous dexamethasone

Group Type: ACTIVE_COMPARATOR

Granisetron Transdermal Patch

Intervention Type: DRUG

Antiemetic

Intravenous Dexamethasone

Intervention Type: DRUG

Antiemetic

ARM 2

ARM 2 -intravenous ondansetron plus intravenous dexamethasone

Group Type: ACTIVE_COMPARATOR

Intravenous Dexamethasone

Intervention Type: DRUG

Antiemetic

Ondansetron

Intervention Type: DRUG

ondansetron

Interventions

Granisetron Transdermal Patch

Antiemetic

Intervention Type: DRUG

Intravenous Dexamethasone

Antiemetic

Intervention Type: DRUG

Ondansetron

ondansetron

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age 18-75 years at time of enrollment receiving either a preparative regimen and either an autologous or allogeneic stem cell transplant.
• No vomiting ≤ 24 hours prior to registration
• No treatment with an antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for ≤ 30 days' prior registration or planned during protocol therapy. No patients will be removed from these treatments for study enrollment purposes.
• No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue antiemetic therapy). No patients will be removed from these treatments for study enrollment purposes.
• No known hypersensitivity to granisetron

Exclusion Criteria

• Concurrent use of amifostine
• Known hypersensitivity to granisetron patch or ondansetron
• Patients with a history of long QT syndrome or Torsade de Pointes

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Illinois at Chicago

OTHER

Sponsor Role: lead

Responsible Party

Karen Sweiss

Clinical Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Karen Sweiss, PharmD

Role: PRINCIPAL_INVESTIGATOR

University of Illinois at Chicago

Locations

University of Illinois Cancer Center

Chicago, Illinois, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Karen Sweiss, PharmD

Role: CONTACT

Phone: 312-996-0875

Email: ksweis2@uic.edu

Facility Contacts

Karen Sweiss, PharmD

Role: primary

Other Identifiers

2019-0886

Identifier Type: -

Identifier Source: org_study_id